TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26434090
Drug: Suprapatellar lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprapatellar lateral injection site
Study: 21173687
Drug: Metenolone enanthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metenolone enanthate (ME) 100 mg injected intramuscularly weekly for 6 weeks
Study: 18313521
Drug: Multicatheter interstitial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicatheter interstitial brachytherapy (n=247) or MammoSite (n=26), receiving 32-34 Gy in 8-10 twice-daily fractions using high-dose-rate 192Ir brachytherapy.
Study: 10579155
Drug: New paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: New paste preparation of Gelfoam powder, Thrombostat, acetic acid, and Bacitracin ointment
Study: 10579155
Drug: Old method
Normalized name: Oldenlandia diffusa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old method using small pieces of Gelfoam soaked in antibiotic solution
Study: 8723582
Drug: Perioperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative treatment with epoetin alfa
Study: 8723582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epoetin alfa and preoperative ABD
Study: 7037511
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified porcine insulin (after removing patients with substantial changes in HbA1)
Study: 7037511
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified porcine insulin (after removing patients with low initial insulin binding capacity)
Study: 7037511
Drug: Bovine insulin
Normalized name: Bovine insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine insulin (after rechallenge)
Study: 26934504
Drug: Post-operative concurrent
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative concurrent radiochemotherapy (p-RTCT)
Study: 24687640
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg nicotine patch applied during the night
Study: 21708892
Drug: Dilute rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute rice vinegar (100 ml daily for 4 weeks)
Study: 21708892
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (100 ml of water)
Study: 14967827
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of caffeine per day for 5 days
Study: 7586105
Drug: Midazolam infusion
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam infusion (0.3-0.5 mg.min-1)
Study: 2239119
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (bolus) followed by 0.25% (infusion)
Study: 2239119
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% (bolus) followed by 0.125% (infusion)
Study: 24637559
Drug: High-dose sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sildenafil
Study: 20479228
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group with newly trained lexical categories for color (e.g., different shades of blue acquiring new names)
Study: 18191684
Drug: Daily spontaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily spontaneous awakening trials (SATs) followed by spontaneous breathing trials (SBTs)
Study: 18191684
Drug: Sedation per
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation per usual care plus a daily SBT
Study: 15625071
Drug: Mupirocin cream
Normalized name: Mupirocin Cream
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin cream
Study: 3093773
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous dextrose infusion
Study: 3093773
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous amino acid infusion
Study: 31712981
Drug: Conventional‐F toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional‐F toothpaste (1,450 μg F/g)
Study: 31712981
Drug: Conventional‐F +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional‐F + arginine/CaCO3 (1,450 μg F/g + 1.5% arginine‐CaCO3)
Study: 31712981
Drug: High‐F toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐F toothpaste (5,000 μg F/g)
Study: 31712981
Drug: High‐F +
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐F + fTCP toothpaste (5,000 μg F/g)
Study: 15910557
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATV)
Study: 26892128
Drug: Ezetimibe/Simvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin + Atorvastatin (E/S + ATV)
Study: 30231121
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard pharmacological treatment)
Study: 23276524
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (combined treatment)
Study: 4044462
Drug: Latamoxef (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latamoxef (1 g)
Study: 4044462
Drug: Cephazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephazolin (1 g) and Metronidazole (500 mg)
Study: 30664407
Drug: Functional-Analytic Psychotherapy
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional-Analytic Psychotherapy and Acceptance and Commitment Therapy (FACT)
Study: 27216710
Drug: Sources of
Normalized name: Dental Resources brand of Stannous Fluoride Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sources of information about HPV vaccine (e.g., doctor or medical professional, television)
Study: 27216710
Drug: Parental attitudes
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental attitudes about HPV vaccine
Study: 27216710
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine uptake
Study: 16283812
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of intrusive force to the maxillary incisors
Study: 16283812
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g of intrusive force to the maxillary incisors
Study: 11011336
Drug: Bisoprolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg
Study: 29783863
Drug: Erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140 mg and subcutaneous sumatriptan 12 mg
Study: 29783863
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo and subcutaneous sumatriptan 12 mg
Study: 21975206
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg MBP8298, given by IV injection once every 6 months for 2 years
Study: 21975206
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given by IV injection once every 6 months for 2 years
Study: 18297821
Drug: Yiqigushen Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqigushen Capsule combined with levofloxacin
Study: 18297821
Drug: Yiqigushen Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqigushen Capsule only
Study: 11213741
Drug: Antibiotic irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic irrigation through canaliculi
Study: 11213741
Drug: Antibiotic irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic irrigation with isolated microorganisms
Study: 11213741
Drug: Antibiotic irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic irrigation with no isolated microorganisms
Study: 9310603
Drug: Modest salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modest salt restriction (5 g salt intake)
Study: 9310603
Drug: Normal salt
Normalized name: SODIUM CHLORIDE 1 g ORAL TABLET [Normal Salt]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal salt intake (10 g salt intake)
Study: 7870975
Drug: Lithium/haloperidol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium/haloperidol treatment
Study: 30041929
Drug: Dalantercept, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalantercept, administered subcutaneously at 1.2 mg/kg every 3 weeks until disease progression or unacceptable toxicity
Study: 27597278
Drug: Thoracic irradiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic irradiation with concomitant weekly paclitaxel (experimental arm)
Study: 27597278
Drug: Thoracic irradiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic irradiation without concurrent chemotherapy (control arm)
Study: 25243839
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 3350‐electrolyte solution (PEG), 4‐L dose
Study: 23522096
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of levothyroxine (target range 4.1 to 8.0 mU/L)
Study: 23522096
Drug: Standard levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard levothyroxine replacement (target range 0.4 to 4.0 mU/L)
Study: 20609969
Drug: Exenatide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (2 mg, once-a-week injection)
Study: 20609969
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (once-daily injection, starting dose 10 IU)
Study: 18835539
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids 8 g/day (EAA group; n=21)
Study: 18835539
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements (controls; n=17)
Study: 14669420
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (LDA, 75 mg daily)
Study: 14669420
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (20 g daily)
Study: 14669420
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid and low molecular weight heparin simultaneously
Study: 14669420
Drug: Isolated occurrence
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated occurrence of lupus anticoagulant antibodies
Study: 14669420
Drug: Occurrence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occurrence of anticardiolipin antibodies
Study: 14669420
Drug: Anticardiolipin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibodies with lupus anticoagulant antibodies simultaneously
Study: 7987976
Drug: ADR-529 (600-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADR-529 (600-1000 mg/m2) with epirubicin (60-100 mg/m2), cyclophosphamide (600 mg/m2), 5-fluorouracil (600 mg/m2), and tamoxifen (30 mg)
Study: 7987976
Drug: Epirubicin (60-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (60-100 mg/m2)
Study: 7987976
Drug: ADR-529 (600-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADR-529 (600-1000 mg/m2)
Study: 3166194
Drug: 0.1% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% NaF solution, applied nine times
Study: 27540904
Drug: Mannitol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 0.25 g/kg (Group A)
Study: 27540904
Drug: Mannitol 0.5
Normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 0.5 g/kg (Group B)
Study: 27540904
Drug: Mannitol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 1.0 g/kg (Group C)
Study: 27540904
Drug: Mannitol 1.5
Normalized name: CYCLOPHOSPHAMIDE 2GM/MANNITOL 1.5GM/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 1.5 g/kg (Group D)
Study: 24247662
Drug: Incentives offered
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incentives offered (antiviral medication, vaccine, double pay, free room and board)
Study: 21364273
Drug: Alfacalcidol 1
Normalized name: alfacalcidol 1 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 1 μg daily + Alendronate 70 mg weekly + 500 mg calcium daily
Study: 21364273
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Alendronate 70 mg weekly + 500 mg calcium daily
Study: 15494330
Drug: Active extracorporeal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active extracorporeal shock wave therapy (2000 pulses, energy flux density 0.03-0.17 mJ/mm(2))
Study: 15494330
Drug: Sham extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham extracorporeal shock wave therapy
Study: 15494330
Drug: Active extracorporeal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active extracorporeal shock wave therapy
Study: 9515521
Drug: Single-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimen of ticarcillin 3.0 g/clavulanate 0.1 g (Timentin)
Study: 9515521
Drug: Multiple-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose regimen of ticarcillin 3.0 g/clavulanate 0.1 g (Timentin)
Study: 8695969
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.30 mg/day plus oral ipriflavone 200 mg tris in die at meals (group C)
Study: 8695969
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus conjugated equine estrogens 0.30 mg/day (group B)
Study: 2085984
Drug: Amoxycillin/clavulanate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (5 days treatment)
Study: 16941068
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (single dose)
Study: 30472886
Drug: Positive perception
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Positive perception of insulin treatment
Study: 30472886
Drug: Only using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only using insulin when alone in public places
Study: 27101422
Drug: Ferric maltol
Normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferric maltol 30 mg twice daily
Study: 27101422
Drug: Ferric maltol
Normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferric maltol 60 mg twice daily
Study: 27101422
Drug: Ferric maltol
Normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferric maltol 90 mg twice daily
Study: 21985332
Drug: Couple's risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple's risk reduction intervention combined with evidence-based medication adherence intervention
Study: 18840576
Drug: Warm priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm priming solution at 36 degrees C
Study: 18840576
Drug: Cold priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold priming solution at 20 degrees C
Study: 17062362
Drug: Deoxyribonucleotidum in
Normalized name: Adenine Deoxyribonucleoside
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deoxyribonucleotidum in addition to routine treatment
Study: 10896369
Drug: Experimental agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental agent
Study: 2014035
Drug: Lidoflazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine (1 mg/kg loading dose, followed by 0.25 mg/kg at 8 and 16 hours after resuscitation)
Study: 7152766
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintained normal daily activities including a 1 day per week physical education class for 8 months
Study: 22325113
Drug: Doxycycline (DOX)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (DOX) 100 mg twice daily for 5 days
Study: 8781634
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg om for 2-4 weeks followed by maintenance omeprazole 20 mg om for one year
Study: 8781634
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course therapy with omeprazole only, followed by placebo
Study: 2187071
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of zidovudine for 18 weeks
Study: 2187071
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day of zidovudine
Study: 2187071
Drug: 1,200 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg/day of zidovudine
Study: 30606815
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg bolus + 0.5-1 mg/h) + 80% hepatectomy
Study: 12855342
Drug: Tramadol (275.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (275.5 mg/day average after dose adaptation)
Study: 10475311
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine for preemptive analgesia in limb surgery
Study: 10475311
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine for preemptive analgesia in mastectomy
Study: 10475311
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine for preemptive analgesia in gastrectomy
Study: 10475311
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine for preemptive analgesia in hysterectomy
Study: 10475311
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine for preemptive analgesia in herniorrhaphy
Study: 10475311
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine for preemptive analgesia in appendectomy
Study: 10475311
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine for preemptive analgesia in hemiorrhaphy
Study: 8595171
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 0.5 mg orally b.d.
Study: 8595171
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 1.0 mg orally b.d.
Study: 8595171
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 2.0 mg orally b.d.
Study: 2015175
Drug: Ibuprofen liquid
Normalized name: ibuprofen Oral Liquid Product
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen liquid in a gelatin capsule
Study: 2015175
Drug: Ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tablets (Nurofen)
Study: 6799415
Drug: Penicillin V,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin V, Amoxicillin, Ampicillin, Erythromycin estolate, Erythromycin ethylsuccinate, Trimethoprim-sulfamethoxazole, Cefaclor
Study: 25666004
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg of intravaginal misoprostol
Study: 25666004
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg of intravaginal misoprostol
Study: 15219299
Drug: Nebulized magnesium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized magnesium sulfate plus albuterol
Study: 15219299
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol plus saline
Study: 9879606
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen of 3 MU for patients with unmodified AMT levels
Study: 9879606
Drug: 24-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-month treatment vs 12-month treatment
Study: 2481532
Drug: Heparin (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (additional administration)
Study: 810198
Drug: Thyrotrophin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin-releasing hormone (TRH) 600 mug, given daily for four days
Study: 810198
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given daily for four days
Study: 28549430
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of reticulated hyaluronic acid (KARTILAGE® CROSS, 16 mg/ml, one single injection of 2.2 mL)
Study: 28549430
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of reticulated hyaluronic acid (KARTILAGE® CROSS)
Study: 23707085
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.2 μg/kg/h for 30 minutes before the procedure, followed by 0.4 μg/kg/h for 6 hours after the procedure)
Study: 23707085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (volume‐matched normal saline solution)
Study: 21718523
Drug: Guided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-based cognitive-behavioral treatment for depression